Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HTR5A | P47898 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TKT | P29401 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1666149 | 0.78 | SCN9A (0.36) | ALDH1A1SMN1; SMN2HTR5AHPGDTSHR | |
| SCHEMBL5055429 | 0.78 | DRD4 (0.47) | TSHR | |
| SCHEMBL5062853 | 0.75 | TNF (0.37) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL1668217 | 0.75 | GRM4 (0.36) | ALDH1A1HTR5AKDM4EHPGD | |
| SCHEMBL15282277 | 0.75 | ALDH1A1 (0.60) | ALDH1A1HPGDTSHRTDP1 | |
| SCHEMBL2331977 | 0.74 | BRD4 (0.33) | ALDH1A1 | |
| SCHEMBL2336000 | 0.73 | TNF (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL29868364 | 0.73 | TNF (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL2360928 | 0.72 | BRD4 (0.39) | — | |
| SCHEMBL4555232 | 0.72 | TNF (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891042-B1 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA SA (BE) | 2013-10-02 | — | — | EP | claimed |
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-23 | — | — | US | claimed |
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-02 | — | — | US | claimed |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2009-12-17 | — | — | US | claimed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | claimed |
| EP-1912966-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB, S.A. (BE) | 2008-04-23 | — | — | EP | claimed |
| EP-1891042-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB Pharma, S.A. (BE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006128692-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | claimed |
| WO-2006128693-A2 | 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | claimed |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2021-08-12 | — | — | US | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
| EP-1912966-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB, S.A. (BE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1891042-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB Pharma, S.A. (BE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128692-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006128693-A2 | 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | ALDH1A1 2177/4885SMN1; SMN2 216/4885KDM1A 832/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | ALDH1A1 1226/4885SMN1; SMN2 104/4885KDM1A 2302/4885 |
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | ALDH1A1 560/4885SMN1; SMN2 2544/4885KDM1A 1830/4885 |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | ALDH1A1 560/4885SMN1; SMN2 2544/4885KDM1A 1830/4885 |
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | ALDH1A1 560/4885SMN1; SMN2 2544/4885KDM1A 1830/4885 |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | OPRD1, PPOX, CYP2D6 | ALDH1A1 447/4885SMN1; SMN2 1086/4885KDM1A 1514/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | ALDH1A1 2177/4885SMN1; SMN2 216/4885KDM1A 832/4885 |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | ALDH1A1 2614/4885SMN1; SMN2 73/4885KDM1A 3145/4885 |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2D, GRIN2A, SLC18A2 | ALDH1A1 2755/4885SMN1; SMN2 428/4885KDM1A 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.